Naučne publikacije akademskog osoblja


Za tačnost unetih podataka o publikacijama, naučnim i umetničkim referencama odgovorni su autori.
Datum kreiranja: 28.09.2021.

Ana Cvetanović

Dodatne informacije

  • Lični podaci

  • Datum rođenja: 01.01.1983
  • Mesto rođenja: Nis
  • Obrazovanje

  • Fakultet: Medicinski fakultet u Nisu
  • Odsek / Grupa / Smer: Medicina
  • Godina diplomiranja: 2007
  • Spisak publikacija

  • Monografije i poglavlja u monografijama:

    1. Cvetanovic A, Popovic L, Zivkovic N, Matovina-Brko G, Kostic M, Vrbic S, Pejcic I. Immune checkpoint inhibitors in the treatment of solid tumors:a new key in the hands of oncologists. In:Watanabe HS.Horizons in cancer research(volume 65). Editor: Watanabe HS. Nova Science Publisher, New York, 2017, 65-90

    2. Cvetanovic A, Filipovic S, Vrbic S, Pejcic I, Popovic L. Side effects of cetuximab rash. In:Maddison RH.Haed and Neck cancer (1st edn). Editor: Maddison RH. Nova Science Publisher, New York, 2015, pp 123-138.

  • Radovi u časopisima sa IMPACT faktorom:

    1.Shaughnessy J, Sousa S, Cruz J, Fallowfield L, Auvinen P, Pulido C, Cvetanovic A, Wilks S, Ribeiro  L , Burotto M, Klingbiel D, Messeri D, Alexandrou A, Trask P, Fredriksson J,  Machackova Z, Stamatovic LJ, PHranceSCa study group. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study. Eur J Cancer 2021;152:223-232.( IF 9.305  M21)

    2.Popovic L,  Matovina-Brko G,  Popovic M, Popovic M,  Cvetanovic A, Nikolic I, Kukic B,  Petrovic D. Immunotherapy in the treatment of lymphoma. World J  Stem Cells 2021; 13(6):503-520. (IF 5.26  M22)

    3.Kostic M, Zivkovic N, Cvetanovic A, Marjanović G. CD4+ T cell phenotypes in the pathogenesis of  immune thrombocytopenia. Cell Immunol 2020; 351:104096 (IF:4.868  M22)

    4.Živković N, Kostić M, Cvetanović A, Milentijević MJ, Spasić M, Petrović M, Trajković M, Denčić T, Krtinić D. Differential challenges in salivary gland neoplasms. Arch Biol Sci 2021; 73(1):65-72. (IF: 0.956  M23)

    5.Dzunic M, Andjelkovic-Apostolovic M, Vrbic S, Pejcic I, Petkovic I, Cvetanovic A, Dinic S. Survival of patients with liver metastases from colorectal cancer treated with bevacizumab and FOLFOX4. J BUON 2020; 25(1):212-9. ( IF: 2.533 (M23)

    6.Trajkovic M, Zivkovic N,  Krasic D, Cosic A,  Lazic V, Stojanovic M, Cvetanovic A, Krasic S. Clinical characteristics and surgical treatment of dacryocystitis - a ten-year retrospective study. Srp Arh Celok Lek 2020; 148(5-6):328-332. (M23)

    7.Dzunic M, Petkovic I, Cvetanovic A, Vrbic S, Pejcic I. Current and future targets and therapies in metastatic colorectal cancer -Status Change. J BUON2019; 24(5):1785-92.  (IF: 1.379 M23)

    8.Ivkovic-Kapic T, Knezevic-Usaj S, Moldvaji E, Jovanic I, Milovanovic Z, Milentijevic M, Tatic S, Mitrovic S, Stojiljkovic M, Cvetanovic A. Interlaboratory concordance in HER2 testing: Results of a Serbian ring-study. J BUON2019; 24(3):1045-1053  (IF: 1.379  M23)

    9.Cvetanovic A, Pejcic I, Zivkovic N, Krtinic D, Kostic M, Popovic L. Do we really know how to overcome trastuzumab resistance in hormone sensitive metastatic breast cancer? J BUON2019; 24(2):516-521.  (IF: 1.379  M23)

    10. Kostic M, Zivkovic N, Cvetanovic A, Stojanovic I. Granulocyte-macrophage colony-stimulating factor as a mediator of autoimmunity in multiple sclerosis. J Neuroimmunol 2018; 323:1-9.   (IF: 2.655  M22)

    11.Krtinic D, Zivadinovic R, Jovic Z, Pesic S, Mihailovic D, Ristic L, Cvetanovic A, Todorovska I, Zivkovic N, Nedin Rankovic G, Stokanovic D, Zivadinovic B, Trandafilovic M, Apostolovic MA, Golubovic M, Zivadinovic A. Significance of the Ki-67 proliferation index in the assessment of the therapeutic response to cisplatin-based chemotherapy in patients with advanced cervical cancer. Eur Rev Med Pharmacol Sci 2018; 22(16):5149-5155. (M22 IF: 2.387)

    12.Popovic L, Tomasevic Z, Stamatovic LJ, Markovic I, Matovina-Brko G, Cvetanovic A, et al. Serbian consensus of neoadjuvant therapy for breast cancer: NeoPULSE. JBUON 2018; 23(2): 522-532. (IF: 1.766 M23)

    13.Cvetanovic A, Filipovic S, Zivkovic N, Popovic L, Kostic M, Djordjevic M, Karanikolic A, Krtinic D.Ten years of using adjuvant trastuzumab in breast cancer in Serbia – Single institution experience. JBUON 2018; 23(2): 353-360 (IF: 1.766 M23)

    14.Kostic M, Zivkovic N, Cvetanovic A, Stojanovic I, Colic M. IL-17 signalling in astrocytes promotes glutamate excitotoxicity: Indications for the link between inflammatory and neurodegenerative events in multiple sclerosis. Multiple Sclerosis and Related Disorders 2017;11: 12–17. (IF: 3.199 М22)

    15.Živković N, Mihailović D, Kostić M, Cvetanović A, Mijović Ž, Milentijević M, Denčić T. Markers of proliferation and cytokeratins in the differential diagnosis of jaw cysts. Ear Nose Throat J 2017; 96(9):376-383.  (IF: 1.010 M23)

    16.Zivkovic N, Mihailovic D, Kostic M, Mijovic Z, Jovicic Milentijevic M, Cvetanovic A, Dencic T, Spasic M. Morphological, immunohistochemical, and morphometric analysis of myoepithelial tumors of the salivary gland. Anal Quant Cytol Histol 2016; 38(6):323-330. (IF: 0.454 M23)

    17.Cvetanovic A, Popovic L, Filipovic S, Trifunovic J, Zivkovic N, Matovina-Brko G, Kostic M, Vicko F, Kocic B, Kolarov-Bjelobrk I. Young Age and Pathological Features Predict Breast Cancer Outcome-Report from a Dual Institution Experience in Serbia. JBUON 2015; 20(6):1407-1413 (M 23 IF 0.741)

    18.Kocic B , Filipovic S, Vrbic S, Pejcic I, Rancic N, Cvetanovic A, Milenkovic D. Stressful life events and breast cancer risk: a hospital-based case-control study. JBUON 2015; 20(2): 487-491. (M23 IF 0.741)

    19.Kostic M, Stojanovic I, Marjanovic G, Zivkovic N, Cvetanovic A. Deleterious versus protective autoimmunity in multiple sclerosis. Cell Immunol. 2015; 296 (2): 122-132. (M 23 IF 1.924)

    20.Petrović D, Mihailović D, Petrović S, Živković N, Mijović Ž, Bjelaković B, Kostić M, Kesić Lj, Stanković A, Petrović M, Vučković I. Asymptomatic flow of Rosai-Dorfman disease. Vojnosanitetski pregled 2014; 71(8): 780-783. (M 24 IF 0.292)

    21.Petkovic I, Krstic M, Pejcic I, Vrbic S, Stojnev S, Cvetanovic A, Balic M, Todorovic M. Renal Infiltration of Follicular Lymphoma. Turkish journal of hematology 2014;31(3):315-316. (M 23 IF 0.360)

    22.Kostic M, Dzopalic T, Zivanovic S, Zivkovic N, Cvetanovic A, Stojanovic I, Vojinovic S, Marjanovic G, Savic V, Colic M. IL-17 and Glutamate Excitotoxicity in the Pathogenesis of Multiple Sclerosis. Scandinavian Journal of Immunology 2014;79(3):181-186. (M 23 IF 1.739)

    23.Pejcic I, Petkovic I, Vrbic S, Filipovic S, Balic M, Cvetanovic A. Mantle cell lymphoma-current literature overview. JBUON 2014; 19(2):342-349. (M23 IF 0.741)

    24.Cvetanović A, Vrbić S, Filipović S, Pejčić I, Milenković D, Živković N, Petković I, Kostić M. Clinical benefit of Cetuximab and prognostic values of Cetuximab-related skin toxicity in metastatic colorectal cancer: a single institution analasys. JBUON 2014; 19(1):83-90. (M23 IF 0.741)

    25.Cvetanovic A, Vrbic S, Filipovic S, Pejcic I, Milenkovic D, Zivkovic N. Safety and efficacy of addition of  bevacizumab to oxaliplatin-based preoperative chemotherapy in colorectal cancer with liver metastasis- a single institution experience. JBUON 2013;18 (3): 641-646. (M23 IF 0.741)

  • Radovi u ostalim časopisima:

    1.Popovic L, Matovina-Brko G, Popovic M, Petrovic D, Cvetanovic A, Vukojevic J, Jovanovic D. High dose chemotherapy with stem cell support in the treatment of testicular cancer. World J Stem Cells 2015; 7(11):1222–1232.   (M 24)

    2. Cvetanović A, Živković N, Kostić M, Džunić M, Jovanović B. Estrogen receptor as a resistance mechanism to  trastuzumab.Acta Medica Medianae 2021;60(1):38-47. (M52)

    3.Živković N, Jovičić-Milentijević M, Cvetanović A, Kostić M, Djordjević M, Krtinić D. Predictive importance of morphometric analysis of  triple-negative breast cancer.Acta Medica Medianae 2020;59(2):38-46.  (M52)

    4.Kostić M, Džopalić T, Živković N, Cvetanović A. Immunomodulatory effects of tgf-β in the patients with immune thrombocytopenia .Acta Medica Medianae 2020;59(2):05-13. (M52)

    5.Krtinić D, Živadinović R, Živadinović B, Jović Z, Pešić S, Pavlović V, Pavlović S, Trandafilović M, Stokanović D, Nedin Ranković G, Cvetanović A, Todorovska I, Živković N, Golubović M. Local therapy with imiquimod as a possible medical treatment of vulvar intraepithelial neoplasms. cta Medica Medianae 2019;58(1):05-10 (M52)

    6.Jović Z, Ristić L, Krtinić D, Nedin-Ranković G, Cvetanović A,  Simić D. The importance of old antibiotics in overcoming resistance to antibiotics. Acta Medica Medianae 2019;58(4):80-84. (M52)

    7.Živković D, Mihailović D, Kostić M, Cvetanović A, Denčić T, Jovičić Milentijević M, Mijović Ž, Stojanović S, Spasić M, Pešić Z, Trajković M. Immunohistochemical and karyometric similarities and differences of salivary gland tumors between pleomorphic adenoma, basal cell adenoma and polymorphous low grade adenocarcinoma. Acta Stomatologica Naissi 2017; 33:1676 -1695. (M52)

    8.Cvetanović A, Filipović S, Živković N, Kostić M, Vrbić S, Pejčić I. Tumor-Infiltrating Lymphocytes and Breast Cancer: Are Immune Checkpoint Inhibitors Ready for Prime Time in Breast Cancer?Acta facultatis medicae Naissensis 2016; 33(4):237-246. (M51)

    9.Pejčić I, Vrbić S, Todorović M, Petković I, Balić M, Stanković A.Cancer of Unknown Primary Site Syndrome- CUP Syndrome - Diagnostic and Therapeutical Dillemas. Acta Facultatis Medicae Naissensis 2014;31(2):87-94. (M51)

    10.Stanković A, Živković N. Possibilities and range of gene therapy. Acta Med Medianae 2011; 50(3):74-80. (M52)

  • Radovi na naučnim skupovima međunarodnog značaja:

    1. Maksic G, Kostic M, Dzopalic T, Zivkovic N, Cvetanovic A.Immunimodulary effect of TGF-b in the patient with immune thrombocytopenia.Eur J I mmunol 2021;51(Suppl 1):P-0550. (M34)

    2.Shaughnessy J, Sousa S, Cruz J, Fallowfield L, Auvinen P, Pulido C, Cvetanovic A, Wilks S, Ribeiro  L , Burotto M, Klingbiel D, Messeri D, Alexandrou A, Trask P, Fredriksson J,  Machackova Z, Stamatovic LJ, PHranceSCa study group. Patient (pt) preference for the pertuzumab-trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study. Ann of Oncol 2020;31 (Suppl):S306-S307  (M34)

    3.Shaughnessy J, Sousa S, Cruz J, Fallowfield L, Auvinen P, Pulido C, Cvetanovic A, Wilks S, Ribeiro  L , Burotto M, Klingbiel D, Messeri D, Alexandrou A, Trask P, Fredriksson J,  Machackova Z, Stamatovic LJ, PHranceSCa study group. Patient (pt) preference and satisfaction with the subcutaneous fixed-dose combination of pertuzumab (P) and trastuzumab (H) in pts with HER2-positive early breast cancer (HER2+eBC): Interim analysis of the open-label, randomised cross-over PHranceSCa study.Ann of Oncol 2020; 31(Suppl. 2):S42-S42. (M34)

    4.Stojanov J, Zikic O, Cvetanovic A, Binic I, Antonijevic J.  Quality of life in patients with breast cancer in relation to oncological characteristics of the disease. Abstracts of the 26th European Congress of Psychiatry In: EUROPEAN PSYCHIATRY, 2019;56:S105  (M34)

    5.Susnjar S, Popovic L, Cvetanovic A, Stanic N, Citic J, Kolarov-Bjelobrk I, Popovic M, Nedovic N, Stojanovic A, Matovina-Brko G, Serovic K, Milosavljevic N, Murtezani Z, Kezic I, Gavrilovic D, Radulovic S. Real world data: Trastuzumab w/o concurrent endocrine therapy in luminal HER2-positive metastatic breast cancer resulted in decreased overall survival. Eur| J Cancer 2018;92(Suppl 3):S112(Abstr PB-024).  (M34)

    6.Krtinić D, Živadinović R, Jović Z, Pavlović V, Pavlović S, Stokanović D, Nedin Ranković G, Todorovka I, Stojanović V, Bojić D, Conić I, Cvetanović A, Antić V, Lilić G, Petrić A. Further diagnostic and therapeutic managment of patients with asc cytological pap findings. 20th International Meeting of the European Society of  Gynaecological Oncology 2017. Abstract book 2017, 806. Vienna, Austria. (M34)

    7.Stanković A. Distribution of white matter lesions in multiple sclerosis. 18th European Students` Conference in Berlin, Germany, 2007. (M34)

    8.Stanković A. Ultrasound in differential diagnosis of salivary gland tumors. 4th Annual Internacional Ain Shams Medical Students` Congress in  Cairo, Egypt, 2006. (M34)

    9.Stanković A. Echosonogaphy in diagnosis of benign and malignant salivary gland tumors. First International Medical Students’ Conress in  Novi Sad 2006. (M34)



  • Radovi na domaćim naučnim skupovima:

    1.Cvetanovic Ana.Dupla anti HER2 blokada je standard adjuvantne hemioterapije HER2 pozitivnog carcinoma dojke visokog rizika.PRO. Drugi srpski senološki kongres. Zbornik sažetaka 2019, 14.Novi Sad, Srbija. (M62)

    2.Cvetanovic Ana.Real world data:Ten years of using adjuvant trastuzumab in breast cancer in Serbia-single institution expirience.2nd Regional Congress of Medical Oncology.Abstract book 2019,2.Belgrade, Serbia  (M62)

    3.Cvetanovic Ana.Sistemsko lecenje CNS metastaza carcinoma dojke.55.Kanceroloska nedelja, Beograd,2018. Anali kanceroloske sekcije SLD  2018:188-189. (M62)

    4.Živković N, Mihailović D, Kostić M, Cvetanović A, Denčić T. Tetralogija Fallot-prikaz slučaja. Aktuelnosti u kardiologiji 6, Niška banja, Srbija, 2017; Balneoclimatologia 2017; 41(1):509-516. (M63)

    5.Kostić M, Džopalić T. Živković N, Cvetanović A, Marjanović G, Vojinović S, Stojanović I, Čolić M. Interakcija Th-17 imunskog odgovora i glutamatske ekscitotoksičnosti: potencijalni značaj u patogenezi multiple sleroze.Svetski dan imunologije-2017. Srpska Akademija Nauka i Umetnosti, Beograd, 2017. (M64)

    6.Živković N, Jovičić Milentijević M, Cvetanović A, Kostić M, Denčić T. Metaplastični karcinom dojke-dijagnostički izazov-prikaz slučaja.36.Timočki medicinski dani, Zaječar, 2017. Timočki medicinski glasnik 2017; 42(1): 49. (M64)

    7.Cvetanovic A. Karcinom dojke kao hronicna bolest: incidence, karakteristike pacijenata I lecenje. 10. Konferencija udruzenja medikalnih onkologa srbije, Beograd 2015. (M62)

    8.Stankovic A, Filipovic S. Karcinom dojke u bolesnice stare 72 godine- prikaz slucaja. 5. Konferenccija udruzenja medikalnih onkologa srbije, Kladovo, maj 2011. (M62)


Poslednji put izmenjeno subota, 02 oktobar 2021 13:25